Click here to return to the Reference Table

Category: Other Neoplasms
Cancer type: Mesothelioma
Descriptor: Therapeutic Development

Reference Number: 417
Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 11, 8122-30 (2005)
PubMed link      E-mail link

Reference Number: 421
Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol. 32, 336-50 (2005)
PubMed link      E-mail link

Reference Number: 661
Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 30, 1097-105 (2009)
PubMed link      E-mail link

Reference Number: 725
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79. Epub 2008 Jul 30 (2009)
PubMed link      E-mail link

Reference Number: 1129
Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 6, 864-74 (2011)
PubMed link      E-mail link

Reference Number: 1702
Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 9(9):e105919 (2014)
PubMed link      E-mail link

Reference Number: 1756
Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 15, 1331-40 (2014)
PubMed link      E-mail link